Samuel Roger1,2, Julien Edeline3, Boris Campillo-Gimenez4,5, Elodie Ventroux3, Marie-Eve Rouge-Bugat6, Anthony Chapron1,2. 1. Department of General Practice, University Rennes, Rennes, France. 2. CHU Rennes, INSERM, CIC 1414 (Centre d'investigation clinique de Rennes), University Rennes, Rennes, France. 3. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. 4. INSERM, LTSI U1099, Rennes, France. 5. Clinical Research Department, Centre Eugene Marquis, Rennes, France. 6. Department of General Practice, University Toulouse, Toulouse, France.
Abstract
BACKGROUND: Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate. OBJECTIVES: The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings. A second objective was to describe the role of the general practitioner (GP) in the management of AEs. METHODS: All patients who started TT at a French Regional Cancer Centre in 2017-2018 were eligible for this 12-month prospective study. A self-administered questionnaire was distributed at inclusion and returned after three months. In the questionnaire, patients listed all AEs that occurred during this period and rated their severity. Occurrence and severity were compared with the rating by a specialised nurse. Patients also indicated the health professional they contacted first for the reported AE. RESULTS: Among the 247 eligible patients, 15 were excluded and 144 responded to the questionnaire. Fourteen different TTs have been prescribed. Asthenia (92.4%) and anorexia (64.6%) were the most frequent AE. Patients' AE severity rating was more severe than the nurse's rating for all drugs (p < 0.001). Patients first contacted their GP for 15.6% of AEs, whereas 20.7% of AEs were not reported to any health professional. CONCLUSION: Patients experienced an average of 4 AEs. AE severity rating was significantly different between patients and nurses. Patients do not always communicate AEs to health care professionals.
BACKGROUND: Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate. OBJECTIVES: The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings. A second objective was to describe the role of the general practitioner (GP) in the management of AEs. METHODS: All patients who started TT at a French Regional Cancer Centre in 2017-2018 were eligible for this 12-month prospective study. A self-administered questionnaire was distributed at inclusion and returned after three months. In the questionnaire, patients listed all AEs that occurred during this period and rated their severity. Occurrence and severity were compared with the rating by a specialised nurse. Patients also indicated the health professional they contacted first for the reported AE. RESULTS: Among the 247 eligible patients, 15 were excluded and 144 responded to the questionnaire. Fourteen different TTs have been prescribed. Asthenia (92.4%) and anorexia (64.6%) were the most frequent AE. Patients' AE severity rating was more severe than the nurse's rating for all drugs (p < 0.001). Patients first contacted their GP for 15.6% of AEs, whereas 20.7% of AEs were not reported to any health professional. CONCLUSION:Patients experienced an average of 4 AEs. AE severity rating was significantly different between patients and nurses. Patients do not always communicate AEs to health care professionals.
Entities:
Keywords:
Adverse effect; ambulatory monitoring; cancer survivors; questionnaire; targeted therapies
Authors: Massimo Di Maio; Ciro Gallo; Natasha B Leighl; Maria Carmela Piccirillo; Gennaro Daniele; Francesco Nuzzo; Cesare Gridelli; Vittorio Gebbia; Fortunato Ciardiello; Sabino De Placido; Anna Ceribelli; Adolfo G Favaretto; Andrea de Matteis; Ronald Feld; Charles Butts; Jane Bryce; Simona Signoriello; Alessandro Morabito; Gaetano Rocco; Francesco Perrone Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: A Bourmaud; A Anota; C Moncharmont; F Tinquaut; M Oriol; V Trillet-Lenoir; A Bajard; S Parnalland; C Rotonda; F Bonnetain; D Pérol; F Chauvin Journal: Br J Cancer Date: 2017-02-14 Impact factor: 7.640
Authors: Richard S Finn; John P Crown; Johannes Ettl; Marcus Schmidt; Igor M Bondarenko; Istvan Lang; Tamas Pinter; Katalin Boer; Ravindranath Patel; Sophia Randolph; Sindy T Kim; Xin Huang; Patrick Schnell; Sashi Nadanaciva; Cynthia Huang Bartlett; Dennis J Slamon Journal: Breast Cancer Res Date: 2016-06-28 Impact factor: 6.466